| Bioactivity | COTI-2, an anti-cancer drug with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation[1][2][3]. | ||||||||||||
| Invitro | COTI-2 efficiently inhibits the proliferation rate of all the tested cell lines following 72 h of treatment. COTI-2 is significantly effective at inhibiting tumor cell proliferation in all three cell lines (COLO-205, HCT-15, and SW620). Relatively low concentrations of COTI-2 are active against all human glioblastoma cell lines tested (U87-MG, SNB-19, SF-268, and SF-295). COTI-2 treatment of SHP-77 cells with approximate IC50 concentrations results in the induction of early apoptosis among 40 to 47% of total cells[2]. | ||||||||||||
| Name | COTI-2 | ||||||||||||
| CAS | 1039455-84-9 | ||||||||||||
| Formula | C19H22N6S | ||||||||||||
| Molar Mass | 366.48 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
COTI-2
CAS: 1039455-84-9 F: C19H22N6S W: 366.48
COTI-2, an anti-cancer drug with low toxicity, is an orally available third generation activator of p53 mutant forms. CO
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.